Effect of C-reactive protein on vascular cells: Evidence for a proinflammatory, proatherogenic role

Current Opinion in Nephrology and Hypertension

Volumn 14, Issue 1, 2005, Pages 33-37

  Venugopal, Senthil Kumar ^a   Devaraj, Sridevi ^a   Jialal, Ishwarlal ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adhesion molecule; Atherosclerosis; C reactive protein; Endothelium; Vascular dysfunction

Indexed keywords

BETA CHEMOKINE; C REACTIVE PROTEIN; FC RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERUM AMYLOID P;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL STRAIN U937; CHEMOTAXIS; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; STEM CELL; UPREGULATION;

ANIMALS; ARTERIOSCLEROSIS; C-REACTIVE PROTEIN; ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; RISK FACTORS; UP-REGULATION;

EID: 12144249151     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200501000-00006     Document Type: Review

References (36)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340:115-126.
2. Libby P. Inflammation in atherosclerosis. Nature 2002; 420:868-874.
3. Jialal I, Devaraj S. Inflammation and atherosclerosis: the value of the high-sensitivity C-reactive protein assay as a risk marker. Am J Clin Pathol 2001; 116 suppl:S108-S115.
4. Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure 1999; 7:169-177.
5. Khreiss T, Jozsef L, Potempa LA, Filep JG. Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation 2004; 109:2016-2022. This study shows that loss of pentameric symmetry in CRP, resulting in formation of mCRP, promotes a proinflammatory HCAEC phenotype through a p38 mitogen-activated protein kinase-dependent mechanism.
6. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111:1805-1812.
7. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107:363-369.
8. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-843.
9. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease - application to clinical and public health practice. Circulation 2003; 107:499-511.
10. Jialal I, Devaraj S. Role of C-reactive protein in the assessment of cardiovascular risk. Am J Cardiol 2003; 91:200-202.
11. Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103:1933-1935.
12. Yasojima K, Schwab C, McGeer EG, et al. Generation of C-rective protein and complement components in atherosclerotic plaques. Am J Pathol 2001; 158:1039-1051.
13. Dong Q, Wright JR. Expression of C-reactive protein by alveolar macrophages. J Immunol 1996; 156:4815-4820.
14. Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003; 108:1930-1932. This study demonstrated that human coronary artery smooth muscle cells, but not human umbilical vein endothelial cells, could produce CRP in response to inflammatory cytokines.
15. Yasojima K, Schwab C, McGeer EG, et al. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res 2000; 887:80-89.
16. Jabs WJ, Logering BA, Gerke P, et al. The kidney as a second site of human C-reactive protein formation in vivo. Eur J Immunol 2003; 33:152-161.
17. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: Risk marker or mediator in atherothrombosis? Hypertension 2004; 44:1-6. An excellent review on CRP, indicating that CRP is a risk marker for cardiovascular disease and also a mediator for atherothrombosis.
18. -/- background the atherosclerosis is increased only in male mice, suggesting a proatherogenic role for CRP in vivo.
19. Venugopal SK, Devaraj S, Yuhanna I, et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002; 106:1439-1441.
20. Venugopal SK, Devaraj S, Jialal I. C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation 2003; 108:1676-1678. This is the first study demonstrated that CRP decreases prostacyclin release from HAECs by inactivating PGIS via nitration caused by increased superoxide anion and inducible nitric oxide synthase expression thus providing mechanistic insight for the first time.
21. 1 activation.
22. Devaraj S, Kumaresan PR, Jialal I. Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. J Mol Cell Cardiol 2004; 36:405-410. This is the first report to show that interleukin-8 expression at RNA and protein levels was increased by CRP via nuclear factor-κB activation in both HAECs and HCAECs.
23. Williams TN, Zhang CX, Game BA, et al. C-reactive protein stimulates MMP-1 expression in U937 histiocytes through FcγRII and extracellular signal-regulated kinase pathway: an implication of CRP involvement in plaque destabilization. Arterioscler Thromb Vasc Biol 2004; 24:61-66. This is the first study demonstrating that CRP stimulates MMP-1 expression by U937 cells through the FcγRII and extracellular signal-regulated kinase pathway.
24. Wang CH, Li SH, Weisel RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003; 107:1783-1790.
25. Verma S, Kuliszewski MA, Li SH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 2004; 109:2058-2067. The first report to show that human recombinant CRP directly inhibits differentiation, survival and function of endothelial progenitor cells, key components of angiogenesis and the response to chronic ischemia. This occurs in part via effect of CRP to reduce endothelial-progenitor-cell endothelial nitric oxide synthase expression.
26. Cermak J, Key NS, Bach RR, et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82:513-520.
27. Paffen E, Vos HL, Bertina RM. C-reactive protein does not directly induce tissue factor in human monocytes. Atheroscler Thromb Vasc Biol 2004; 24:975-981. This study demonstrated that the absence of tissue-factor induction after incubation of purified monocytes with CRP indicates that CRP is unable to induce tissue-factor expression in monocytes directly. The presence of CRP-induced tissue-factor expression in peripheral mononuclear cells suggests that CRP can induce tissue factor indirectly, probably through crosstalk between cells.
28. Nagoshi Y, Kuwasako K, Cao YN, et al. Effects of C-reactive protein on atherogenic mediators and adrenomedullin in human coronary artery endothelial and smooth muscle cells. Biochem Biophys Res Commun 2004; 31:1057-1063. This is a report showing that CRP inhibits adrenomedullin production in both HCAECs and vascular smooth muscle cells.
29. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003; 107:398-404.
30. Danenberg HD, Szalai AJ, Swaminathan RV, et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 2003; 108:512-515. This is the first in-vivo study showing in human CRP transgenic mice there was an increased atherothrombosis.
31. Pepys MB, Baltz M, Gomer K, et al. Serum amyloid P-component is an acute-phase reactant in the mouse. Nature 1979; 278:259-261.
32. Szalai AJ, Briles DE, Volanakis JE. Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in transgenic mice. J Immunol 1995; 155:2557-2563.
33. Rowe IF, Soutar AK, Trayner IM, et al. Rabbit and rat C-reactive proteins bind apolipoprotein B-containing lipoproteins. J Exp Med 1984; 159:604-616.
34. Griselli M, Herbert J, Hutchinson WL, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999; 190:1733-1740.
35. Ikeda U, Maeda Y, Yamamoto K, Shimada K. C-Reactive protein augments inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes. Cardiovasc Res 2002; 56:86-92.
36. Hattori Y, Matsumura M, Kasai K. Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc Res 2003; 58:186-195.